PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
PTC Therapeutics (PTCT) Tops Q1 EPS by 18c
May 8, 2017 7:31 AM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.85), $0.18 better than the analyst estimate of ($1.03). Revenue for the quarter came in at $26.5 million versus the consensus estimate of $28.65 million.
"We are thrilled to bring EMFLAZA to Duchenne muscular dystrophy patients in the United States,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "The acquisition of EMFLAZA supports our commitment to providing new treatment options for Duchenne patients. We plan to launch EMFLAZA in the coming weeks and are focused on providing access to all eligible patients. We are also pleased... More
